Moleculin Biotech Inc. (NASDAQ:MBRX) stock is trading lower on Tuesday after the company shared prel

Moleculin reports interim Phase 2/3 trial data as Annamycin shows higher remission rates than contro

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announ

Both Annamycin dose arms outperformed control on the primary endpoint of complete remission (CR): 43

Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular sessi

Gainers HeartSciences (NASDAQ:HSCS) stock rose 82.2% to $3.23 during Tuesday's pre-market sessi

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announc

The poster presentation, titled "Cardiac safety of L-annamycin at high cumulative anthracycline

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(3.54) per share which missed the anal

Moleculin Biotech nears first MIRACLE trial data unblinding as Annamycin shows higher remission rate

Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~

The abstract titled, "Cardiac Safety of L-Annamycin Across High Cumulative Anthracycline Exposur

Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data ReleaseH

HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy an

This milestone triggers the final phase of preparation for the trial's interim 45 subject data u

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(26.06) per share which missed the ana

Preliminary blinded CR rate showed 67% improvement over historical cytarabine responseRoughly 35% of

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announc

– Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials– Thi

As previously disclosed, on May 23, 2025, Moleculin Biotech, Inc. (the "Company") received a

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announ

HC Wainwright & Co. analyst Sara Nik maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage

Continues to drive enrollment with increase to 78% now consentedBlinded response activity tracking w

Investigator-Initiated Preclinical studies at CIC biomaGUNE aimed at combatting Glioblastoma Multifo

Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), today announ

Preclinical research to be conducted at the University of North Carolina at Chapel Hill (UNC) Annamy

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage

Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a late-stage

HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy an

Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a late-stage

Spain site opens with two R/R AML subjects enrolled; One treatedOn track to recruit 45 subjects in 4

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage

HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy an

Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8)Median OS of 2nd

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(0.49) per share which missed the anal

Presented data highlights the potential of Annamycin for treating broad range of human cancers, incl